Alzheimer's drugs show little real benefit, major review finds

A new Cochrane review оцales 17 studies with 20,342 participants, most with mild cognitive impairment or dementia and a mean age of 70 to 74. It concludes that the effects of anti-amyloid medicines on cognitive function and dementia severity after 18 months are either absent or only trivial. The drugs studied include lecanemab and donanemab, which are licensed for use in the UK, along with others such as aducanumab, bapineuzumab, crenezumab and solanezumab, many of which were abandoned after failed trials. The analysis targets how these medicines slow disease progression and whether their benefits justify their costs and risks, such as brain swelling and bleeding that have accompanied some treatments.

In the UK, the National Institute for Health and Care Excellence (Nice) has deemed the benefits of these anti-amyloid therapies to be too small to justify widespread NHS funding, even as the drugs hold licenses for use. The review’s authors say their findings do not necessarily apply to every individual drug or every cohort, and they caution against painting an entire class of therapies with the same brush. Charities and patient groups have challenged this framing, arguing that combining failed and successful trials risks obscuring potential benefits for certain patients and emerging treatments.

The debate spills beyond numbers: clinicians, patients and families want clear guidance on who, if anyone, may benefit, and at what cost. While the new analysis adds to questions about the overall value of anti-amyloid drugs, it also underscores the need for more precise, patient-centered research. As the field continues to evolve, stakeholders are calling for nuanced assessments that reflect real-world outcomes, safety profiles, and individual patient circumstances.

#AlzheimersDrugs #CochraneReview #DementiaResearch